JPMorgan upgrades Afya stock rating to Overweight on solid performance

JPMorgan upgraded Brazilian education company Afya Ltd. (NASDAQ:AFYA) to Overweight from Neutral, raising its price target to $24.50, implying a 63% potential upside. This upgrade is driven by Afya's strong Q2 2025 earnings, which saw EPS significantly beat expectations despite a minor revenue miss, alongside consistent performance, robust 65% gross margins, and a perceived undervaluation. JPMorgan highlights the "interesting risk/reward combo" for investors, despite the stock's relatively low trading liquidity.

Analysis

JPMorgan has upgraded Afya Ltd. (NASDAQ:AFYA) to Overweight from Neutral, raising its price target to $24.50, which implies a significant 63% potential upside from current levels. This bullish revision is founded on the Brazilian education company's consistent performance, including a track record of meeting guidance since its 2019 IPO, and its solid second-quarter 2025 results. Despite a slight revenue miss for the quarter ($919.4 million versus a $935.49 million forecast), Afya demonstrated notable financial resilience and profitability by delivering an EPS of $2.27, which surpassed expectations by 14.65%. The company's strong fundamentals are further evidenced by impressive gross margins of approximately 65% and a 15.6% revenue growth over the last twelve months. However, JPMorgan tempers its outlook by highlighting the stock's relatively low daily trading liquidity of around $2 million, categorizing it as an "interesting risk/reward combo" primarily suited for investors who can manage illiquid positions.

Key Decisions for Investors

• Investors could consider the stock attractive given the strong analyst upgrade, significant price target upside, and demonstrated ability to deliver high profitability even with revenue shortfalls.
• The low daily trading liquidity of approximately $2 million is a key risk factor that must be assessed, as it could complicate entry and exit for large positions and increase volatility.
• Focus on the company's ability to maintain its industry-leading gross margins of ~65%, as this is a core driver of its financial resilience and the positive investment thesis.
• Note that the new $24.50 price target is based on a long-term December 2026 outlook, suggesting this is a thesis for investors with a multi-year time horizon.